Symbols

RLYB

Rallybio·NASDAQ

--(--)

Signals Analysis

Bullish signal 2

Bearish signal 1

Bearish Engulfing

Ample Liquidity

High Gross Profit Margin

Key Stats

0.0000DAY`S RANGE0.0000

0.000052 WK RANGE0.0000

Open

0.0000

Prev.Close

0.0000

%Range

Turnover

Avg Vol(4W)

Market Cap

Div.Yield

P/E(TTM)

EPS(TTM)

Beta

Free Float

Shares Outstanding

%Turnover

P/E(DYN)

P/B

BVPS

High

0.0000

Low

0.0000

52 Week High

0.0000

52 Week Low

0.0000

About RLYB

Rallybio Corporation

A biotech company focused on developing life-changing therapies for rare diseases

Industry

Life Science Tools and Services

Established Date

03/22/2018

Listing Date

07/29/2021

Exchange

NASDAQ Stock Exchange

Full-time Employees

Fiscal Year Ends

12-31

Website

www.rallybio.com

Security Type

Common stock

Office address

234 Church Street New Haven CT 06510

Business

Introduction

Rallybio Corporation was incorporated in Delaware on March 22, 2018. The Company is a clinical-stage biotechnology company comprised of experienced biopharmaceutical industry leaders with extensive research, development and rare disease expertise, and its mission is to develop and commercialize life-changing therapies for patients with serious and rare diseases. Since its launch in January 2018, the company has built a broad pipeline of promising product candidates designed to address diseases with unmet medical needs in areas such as maternal and fetal health, complement disorders, hematology and metabolic disorders. Two of the company's most advanced programs are in clinical development: RLYB212, an anti-HPA-1a antibody for the prevention of fetal and neonatal alloimmune thrombocytopenia (" FNAIT "), and RLYB116, an inhibitor of complement component 5 (" C5 "), which has the potential to treat several complement disorder diseases.

Company Financials

EPS

RLYB has released its 2025 Q3 earnings. EPS was reported at 0.36, versus the expected -0.2, beating expectations. The chart below visualizes how RLYB has performed over recent quarters, highlighting trends in earnings surprises.

Revenue & Expenses

RLYB has released its 2025 Q4 earnings report, with revenue of 222.00K, reflecting a YoY change of 484.21%, and net profit of -5.85M, showing a YoY change of 47.01%. The Sankey diagram below clearly presents RLYB's revenue sources and cost distribution.